270 related articles for article (PubMed ID: 3681191)
21. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
Kim YR; Yoo JH; Hur JK; Kang JH; Shin WS; Kang MW
J Korean Med Sci; 1995 Oct; 10(5):314-7. PubMed ID: 8750055
[TBL] [Abstract][Full Text] [Related]
23. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
Klugman KP; Gilbertson IT; Koornhof HJ; Robbins JB; Schneerson R; Schulz D; Cadoz M; Armand J
Lancet; 1987 Nov; 2(8569):1165-9. PubMed ID: 2890805
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
[TBL] [Abstract][Full Text] [Related]
25. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
[TBL] [Abstract][Full Text] [Related]
26. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
Voysey M; Pollard AJ
Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
[TBL] [Abstract][Full Text] [Related]
27. S.Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice.
Haque S; Sengupta S; Gupta D; Bhan MK; Kumar R; Khan A; Jailkhani B
Biologicals; 2019 Nov; 62():50-56. PubMed ID: 31606267
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of purified Vi polysaccharide typhoid vaccine.
Park JH; Hong JJ; Choi ES; Lee JW; Park JH
J Vet Sci; 2002 Jun; 3(2):67-70. PubMed ID: 12441674
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine--vax-TyVi--in Cuban school children and teenagers.
Azze RF; Rodríguez JC; Iniesta MG; Marchena XR; Alfonso VM; Padrón FT
Vaccine; 2003 Jun; 21(21-22):2758-60. PubMed ID: 12798615
[TBL] [Abstract][Full Text] [Related]
30. Salmonella typhi O:9,12 polysaccharide-protein conjugates: characterization and immunoreactivity with pooled and individual normal human sera, sera from patients with paratyphoid A and B and typhoid fever, and animal sera.
Aron L; Di Fabio J; Cabello FC
J Clin Microbiol; 1993 Apr; 31(4):975-8. PubMed ID: 7681853
[TBL] [Abstract][Full Text] [Related]
31. Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever.
Giannelli C; Cappelletti E; Di Benedetto R; Pippi F; Arcuri M; Di Cioccio V; Martin LB; Saul A; Micoli F
J Pharm Biomed Anal; 2017 May; 139():143-147. PubMed ID: 28282600
[TBL] [Abstract][Full Text] [Related]
32. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
Front Immunol; 2020; 11():574057. PubMed ID: 33424833
[TBL] [Abstract][Full Text] [Related]
33. [Conjugate vaccines against bacterial infections: typhoid fever].
Paniagua J; García JA; López CR; González CR; Isibasi A; Kumate J
Salud Publica Mex; 1992; 34(3):268-73. PubMed ID: 1377407
[TBL] [Abstract][Full Text] [Related]
34. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity.
An SJ; Yoon YK; Kothari S; Kothari N; Kim JA; Lee E; Kim DR; Park TH; Smith GW; Carbis R
Vaccine; 2011 Oct; 29(44):7618-23. PubMed ID: 21843575
[TBL] [Abstract][Full Text] [Related]
35. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate.
Fattom A; Shiloach J; Bryla D; Fitzgerald D; Pastan I; Karakawa WW; Robbins JB; Schneerson R
Infect Immun; 1992 Feb; 60(2):584-9. PubMed ID: 1730492
[TBL] [Abstract][Full Text] [Related]
36. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
Wetter M; Kowarik M; Steffen M; Carranza P; Corradin G; Wacker M
Glycoconj J; 2013 Jul; 30(5):511-22. PubMed ID: 23053636
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates.
Fattom A; Vann WF; Szu SC; Sutton A; Li X; Bryla D; Schiffman G; Robbins JB; Schneerson R
Infect Immun; 1988 Sep; 56(9):2292-8. PubMed ID: 3410538
[TBL] [Abstract][Full Text] [Related]
38. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
39. The need & the issues related to new-generation typhoid conjugate vaccines in India.
Vashishtha VM; Kalra A
Indian J Med Res; 2020 Jan; 151(1):22-34. PubMed ID: 32134011
[TBL] [Abstract][Full Text] [Related]
40. Immunological evaluation of Vi capsular polysaccharide of Salmonella enterica subsp. Typhi vaccine by serum bactericidal assay.
Ahmadi H; Tabaraie B; Maleknia S; Shapouri R; Nejati M; Pour Mirza Gholi F; Hedayati M; Sadati M; Zahednia S; Sharifat Salmani A
J Med Microbiol; 2013 Feb; 62(Pt 2):283-286. PubMed ID: 23105026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
